HRP20100568T1 - Rekombinantno modificiran plazmin - Google Patents

Rekombinantno modificiran plazmin Download PDF

Info

Publication number
HRP20100568T1
HRP20100568T1 HR20100568T HRP20100568T HRP20100568T1 HR P20100568 T1 HRP20100568 T1 HR P20100568T1 HR 20100568 T HR20100568 T HR 20100568T HR P20100568 T HRP20100568 T HR P20100568T HR P20100568 T1 HRP20100568 T1 HR P20100568T1
Authority
HR
Croatia
Prior art keywords
polypeptide
seq
polynucleotide
lysine
domain
Prior art date
Application number
HR20100568T
Other languages
English (en)
Croatian (hr)
Inventor
Audrey Hunt Jennifer
Novokhatny Valery
Original Assignee
Talecris Biotherapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34982338&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20100568(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Talecris Biotherapeutics filed Critical Talecris Biotherapeutics
Publication of HRP20100568T1 publication Critical patent/HRP20100568T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HR20100568T 2004-04-22 2005-04-21 Rekombinantno modificiran plazmin HRP20100568T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56447204P 2004-04-22 2004-04-22
PCT/US2005/013562 WO2005105990A2 (fr) 2004-04-22 2005-04-21 Plasmine a modification par recombinaison

Publications (1)

Publication Number Publication Date
HRP20100568T1 true HRP20100568T1 (hr) 2010-11-30

Family

ID=34982338

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20100568T HRP20100568T1 (hr) 2004-04-22 2005-04-21 Rekombinantno modificiran plazmin

Country Status (27)

Country Link
US (2) US8034913B2 (fr)
EP (2) EP2246417B1 (fr)
JP (1) JP5026254B2 (fr)
KR (1) KR101161819B1 (fr)
CN (2) CN1961070A (fr)
AT (1) ATE476502T1 (fr)
AU (1) AU2005238464B2 (fr)
BR (1) BRPI0510063B8 (fr)
CA (1) CA2563675C (fr)
CY (1) CY1111650T1 (fr)
DE (1) DE602005022692D1 (fr)
DK (1) DK1740698T3 (fr)
EA (1) EA010784B1 (fr)
ES (2) ES2349555T3 (fr)
HR (1) HRP20100568T1 (fr)
IL (1) IL178343A (fr)
MA (1) MA28590B1 (fr)
MX (1) MXPA06012236A (fr)
NO (1) NO338542B1 (fr)
NZ (1) NZ550250A (fr)
PL (2) PL1740698T3 (fr)
PT (2) PT2246417E (fr)
RS (1) RS51623B (fr)
SI (1) SI1740698T1 (fr)
TN (1) TNSN06332A1 (fr)
WO (1) WO2005105990A2 (fr)
ZA (1) ZA200608498B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7659445B2 (en) 2004-02-11 2010-02-09 Biolex Therapeutics, Inc. Expression of plasminogen and microplasminogen in duck weed
MXPA06012236A (es) 2004-04-22 2007-01-31 Talecris Biotherapeutics Inc Plasmina modificada en forma recombinante.
WO2007047874A2 (fr) * 2005-10-20 2007-04-26 Talecris Biotherapeutics, Inc. Plasmine modifiée par recombinaison
KR100888022B1 (ko) * 2006-12-21 2009-03-09 재단법인 목암생명공학연구소 면역글로불린 Ｆｃ와 인간 아포리포단백질（ａ）크링글절편의 융합단백질 ＬＫ8­Ｆｃ
JP5539896B2 (ja) 2007-11-29 2014-07-02 グリフオルス・セラピユーテイクス・インコーポレーテツド 組換え的に改変されたプラスミン
NZ589557A (en) 2008-06-04 2012-08-31 Talecris Biotherapeutics Inc Immobilised streptokinase, method and kit for preparing plasmin
HUE025670T2 (en) 2009-03-03 2016-04-28 Grifols Therapeutics Inc A method for producing plasminogen
EP2451835A1 (fr) 2009-07-10 2012-05-16 ThromboGenics N.V. Variantes du plasminogène et de la plasmine
ES2534911T3 (es) 2009-08-28 2015-04-30 Thrombogenics N.V. Uso de plasmina para el tratamiento de fallo de filtración después de trabeculectomía
RU2432397C2 (ru) * 2009-11-24 2011-10-27 Федеральное государственное учреждение "Российский кардиологический научно-производственный комплекс" Министерства здравоохранения и социального развития Российской Федерации (ФГУ "РКНПК" Минздравсоцразвития России) РЕКОМБИНАНТНЫЙ ПОЛИПЕПТИД СО СВОЙСТВАМИ ПЛАЗМИНОГЕНА ЧЕЛОВЕКА ПРЕВРАЩАТЬСЯ ПРИ АКТИВАЦИИ В ПЛАЗМИН, КОТОРЫЙ КАТАЛИЗИРУЕТ РАСЩЕПЛЕНИЕ ФИБРИНА, ФРАГМЕНТ ДНК, КОДИРУЮЩИЙ ПОЛИПЕПТИД, РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК ДЛЯ ЭКСПРЕССИИ ПОЛИПЕПТИДА И ТРАНСФОРМИРОВАННАЯ КЛЕТКА Escherichia coli - ПРОДУЦЕНТ ПОЛИПЕПТИДА
RU2432396C2 (ru) * 2009-11-24 2011-10-27 Федеральное государственное учреждение "Российский кардиологический научно-производственный комплекс" Министерства здравоохранения и социального развития Российской Федерации (ФГУ "РКНПК" Минздравсоцразвития России) РЕКОМБИНАНТНЫЙ ПОЛИПЕПТИД СО СВОЙСТВАМИ ПЛАЗМИНОГЕНА ЧЕЛОВЕКА ПРЕВРАЩАТЬСЯ ПРИ АКТИВАЦИИ В ПЛАЗМИН, КОТОРЫЙ КАТАЛИЗИРУЕТ РАСЩЕПЛЕНИЕ ФИБРИНА, ФРАГМЕНТ ДНК, КОДИРУЮЩИЙ ПОЛИПЕПТИД, РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК ДЛЯ ЭКСПРЕССИИ ПОЛИПЕПТИДА И ТРАНСФОРМИРОВАННАЯ КЛЕТКА Escherichia coli - ПРОДУЦЕНТ ПОЛИПЕПТИДА
RU2604807C2 (ru) 2011-01-05 2016-12-10 ТромбоДженикс НВ Варианты плазминогена и плазмина
JP6000353B2 (ja) 2011-08-12 2016-09-28 スロンボジェニックス・ナムローゼ・フェンノートシャップＴｈｒｏｍｂｏＧｅｎｉｃｓ ＮＶ プラスミノーゲンおよびプラスミンの変異体
TWI624267B (zh) * 2015-12-18 2018-05-21 Talengen Institute Of Life Sciences Co Ltd 纖溶酶原在製備預防或治療糖尿病性視網膜病變的藥劑上的用途及包括纖溶酶原用於預防或治療糖尿病性視網膜病變之藥劑
US11129880B2 (en) 2016-12-15 2021-09-28 Talengen International Limited Method for promoting insulin secretion
TW201822805A (zh) 2016-12-15 2018-07-01 深圳瑞健生命科學硏究院有限公司 一種預防和治療脂肪異常沉積導致的組織損傷的方法
CN108210914A (zh) * 2016-12-15 2018-06-29 深圳瑞健生命科学研究院有限公司 预防和治疗脂肪代谢紊乱及其相关病症的药物及其用途
TW201829448A (zh) 2016-12-15 2018-08-16 大陸商深圳瑞健生命科學硏究院有限公司 纖溶酶原在製備預防或治療肥胖症及疾病倂發的肥胖的藥物中的用途
EP4140498A4 (fr) 2020-05-11 2023-11-01 Talengen International Limited Procédé et médicament pour le traitement d'une amyotrophie spinale
AR124640A1 (es) 2020-11-25 2023-04-19 Grifols Worldwide Operations Ltd Cicatrización de heridas
US11964004B2 (en) * 2021-03-31 2024-04-23 Shenzhen Bay Laboratory Short in vivo half-life and in vivo unstable recombinant microplasmin, pharmaceutical composition comprising thereof and method of treating thromboembolism related diseases including administration thereof
AU2023309803A1 (en) 2022-07-22 2025-01-09 Grifols Worldwide Operations Limited Stable plasmin compositions for organ preservation and reconditioning
WO2025235230A1 (fr) * 2024-05-07 2025-11-13 The Scripps Research Institute Molécules de plasmine modifiées et compositions associées pour le traitement de la thrombose
CN119331857B (zh) * 2024-12-19 2025-05-16 南通大学 一种新型重组蛋白Plasminogen-CTM及应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4652639A (en) 1982-05-06 1987-03-24 Amgen Manufacture and expression of structural genes
US4631211A (en) 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
US5149533A (en) * 1987-06-04 1992-09-22 Zymogenetics, Inc. Modified t-PA with kringle-/replaced by another kringle
US4774087A (en) * 1987-08-14 1988-09-27 Northwestern University Micro-size fibrinolytic plasmin
US7253264B1 (en) 1990-06-28 2007-08-07 Sanofi-Arentideutschland GmbH Immunoglobulin fusion proteins, their production and use
ATE169030T1 (de) 1990-06-28 1998-08-15 Hoechst Ag Fusionsproteine mit immunglobulinanteilen, ihre herstellung und verwendung
US6312893B1 (en) 1996-01-23 2001-11-06 Qiagen Genomics, Inc. Methods and compositions for determining the sequence of nucleic acid molecules
EP0868535B9 (fr) 1996-01-23 2007-05-09 Qiagen Genomics, Inc. Procedes et compositions permettant de determiner la sequence de molecules d'acides nucleiques
US6613508B1 (en) 1996-01-23 2003-09-02 Qiagen Genomics, Inc. Methods and compositions for analyzing nucleic acid molecules utilizing sizing techniques
JPH10158300A (ja) 1996-11-28 1998-06-16 Suzuki Motor Corp 血管新生抑制効果を有するタンパク質とその製造方法及びアンギオスタチンの製造方法
WO1999005322A1 (fr) 1997-07-22 1999-02-04 Rapigene, Inc. Procede et systeme informatiques pour la mise en correlation de donnees de sequençage par spectometre de masse
JP2002520367A (ja) 1998-07-14 2002-07-09 ブリストル−マイヤーズ スクイブ カンパニー アンギオスタチンのリジン結合フラグメント
WO2000018436A1 (fr) 1998-09-29 2000-04-06 Leuven Research & Development Vzw UTILISATION DE COMPOSES DE REDUCTION DES α2-ANTIPLASMINES IN-VIVO POUR LA PREPARATION D'UNE COMPOSITION THERAPEUTIQUE CONTRE L'ACCIDENT ISCHEMIQUE CEREBRAL
US6964764B2 (en) 1999-11-13 2005-11-15 Talecris Biotherapeutics, Inc. Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
US6969515B2 (en) 1999-11-13 2005-11-29 Talecris Biotherapeutics, Inc. Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
US6355243B1 (en) 1999-11-13 2002-03-12 Bayer Corporation Method of thrombolysis by local delivery of active plasmin
WO2001094366A1 (fr) 2000-06-02 2001-12-13 Blue Heron Biotechnology, Inc. Methode visant a ameliorer la fidelite sequentielle des oligonucleotides synthetiques bicatenaires
DK1343903T3 (da) 2000-12-21 2008-03-10 Thrombogenics Nv En gærekspressionsvektor og en fremgangsmåde til fremstilling af et rekombinant protein ved ekspression i en gærcelle
AU2002357249A1 (en) 2001-12-13 2003-07-09 Blue Heron Biotechnology, Inc. Methods for removal of double-stranded oligonucleotides containing sequence errors using mismatch recognition proteins
US20050124036A1 (en) 2002-02-06 2005-06-09 Rudy Susilo Method for producing recombinant proteins in micro-organisms
US7776026B2 (en) 2002-02-06 2010-08-17 Nuvue Technologies, Inc. Method for vitreous liquefaction
GB0228409D0 (en) 2002-12-06 2003-01-08 Thromb X Nv Pharmacological vitreolysis
MXPA06012236A (es) 2004-04-22 2007-01-31 Talecris Biotherapeutics Inc Plasmina modificada en forma recombinante.
WO2007047874A2 (fr) 2005-10-20 2007-04-26 Talecris Biotherapeutics, Inc. Plasmine modifiée par recombinaison
JP5539896B2 (ja) 2007-11-29 2014-07-02 グリフオルス・セラピユーテイクス・インコーポレーテツド 組換え的に改変されたプラスミン

Also Published As

Publication number Publication date
ES2534744T3 (es) 2015-04-28
WO2005105990A3 (fr) 2006-01-12
ATE476502T1 (de) 2010-08-15
HK1150242A1 (en) 2011-11-11
US8420079B2 (en) 2013-04-16
US20100304465A1 (en) 2010-12-02
NZ550250A (en) 2009-05-31
KR101161819B1 (ko) 2012-07-03
EA200601950A1 (ru) 2007-02-27
CY1111650T1 (el) 2015-10-07
CN102660564A (zh) 2012-09-12
EP2246417B1 (fr) 2015-01-21
IL178343A (en) 2010-11-30
ES2349555T3 (es) 2011-01-05
BRPI0510063B1 (pt) 2020-03-17
EP2246417A1 (fr) 2010-11-03
SI1740698T1 (sl) 2010-11-30
TNSN06332A1 (en) 2008-02-22
MXPA06012236A (es) 2007-01-31
BRPI0510063B8 (pt) 2021-05-25
RS51623B (sr) 2011-08-31
IL178343A0 (en) 2007-02-11
NO20065050L (no) 2006-11-03
CN102660564B (zh) 2013-05-08
EP1740698B1 (fr) 2010-08-04
AU2005238464A1 (en) 2005-11-10
EP1740698A2 (fr) 2007-01-10
WO2005105990A2 (fr) 2005-11-10
ZA200608498B (en) 2008-07-30
CA2563675C (fr) 2012-08-28
DE602005022692D1 (de) 2010-09-16
US20110318812A1 (en) 2011-12-29
NO338542B1 (no) 2016-09-05
BRPI0510063A (pt) 2008-03-11
HK1175812A1 (en) 2013-07-12
EA010784B1 (ru) 2008-10-30
PL1740698T3 (pl) 2011-01-31
PL2246417T3 (pl) 2015-06-30
PT1740698E (pt) 2010-11-02
DK1740698T3 (da) 2010-10-25
MA28590B1 (fr) 2007-05-02
HK1099341A1 (en) 2007-08-10
CN1961070A (zh) 2007-05-09
US8034913B2 (en) 2011-10-11
PT2246417E (pt) 2015-05-05
JP5026254B2 (ja) 2012-09-12
AU2005238464B2 (en) 2011-01-27
JP2007533327A (ja) 2007-11-22
KR20070006918A (ko) 2007-01-11
CA2563675A1 (fr) 2005-11-10

Similar Documents

Publication Publication Date Title
CA2563675A1 (fr) Plasmine a modification par recombinaison
Rodrigues et al. Structural and functional characterization of neuwiedase, a nonhemorrhagic fibrin (ogen) olytic metalloprotease from Bothrops neuwiedi snake venom
Sottrup-Jensen et al. Amino-acid sequence of activation cleavage site in plasminogen: homology with" pro" part of prothrombin.
NZ593837A (en) Recombinantly modified plasmin
Lengyel et al. Affinity purification of recombinant trypsinogen using immobilized ecotin
AU9605898A (en) Chimeric serine protiases
Zheng et al. Purification, characterization and gene cloning of Da-36, a novel serine protease from Deinagkistrodon acutus venom
Park et al. Cloning and characterization of novel disintegrins from Agkistrodon halys venom
Hahn et al. Purification and characterization of a serine protease with fibrinolytic activity from Tenodera sinensis (praying mantis)
Baek et al. A novel family of ubiquitin-specific proteases in chick skeletal muscle with distinct N-and C-terminal extensions
Tan Isolation and characterization of the thrombin-like enzyme from Cryptelytrops purpureomaculatus venom
Pirkle et al. Catroxobin, a weakly thrombin-like enzyme from the venom of Crotalus atrox. NH2-terminal and active site amino acid sequences
Jiao et al. Characterization of a recombinant chimeric plasminogen activator with enhanced fibrin binding
Buniya et al. Cloning and expression of hybrid streptokinase towards clot-specific activity
Friedrich et al. An isopeptide bond splitting enzyme from Hirudo medicinalis similar to γ‐glutamyl transpeptidase
Zhang et al. Functional properties of a recombinant chimeric plasminogen activator with platelet-targeted fibrinolytic and anticoagulant potential
Chen et al. A novel high molecular weight metalloproteinase cleaves fragment F1 of activated human prothrombin
Franke et al. Engineering the oxyanion hole of trypsin for promoting the reverse of proteolysis
Arbelaez et al. Proteinases from the fibrinolytic and coagulation systems: Analyses of binding to pregnancy zone protein, a pregnancy-associated plasma proteinase inhibitor
DK0819173T3 (da) Mutant af inhibitoren af Erythrina caffra-typen og anvendelse deraf til oprensning af serinproteaser
Zhang et al. Expression and characterization of ARSP1 from Eisenia fetida
Jiao et al. Construction and characterization of a recombinant chimeric plasminogen activator consisting of a fibrin peptide and a low molecular mass single-chain urokinase
Fischer et al. Purification of human tissue‐type plasminogen activator (t‐PA) from melanoma cell culture medium by different affinity chromatographic methods
Gombos HUMAN TRYPSIN 4: INSIGHT INTO THE MOLECULAR WORLD OF THE
Le Bonniec STRUCTURE–FUNCTION RELATIONSHIP IN THE PLASMINOGEN ACTIVATOR ISOLATED FROM THE VENOM OF TRIMERESURUS STEJNEGERI